TLPHTalphera, Inc.
Sign up free
Thesis

Nafamostat racing a Q4 2026 cash cliff: NEPHRO CRRT primary endpoint determines whether PMA filing and the contingent $12M tranche arrive in time

Updated 34d ago

Talphera is a clinical-stage company developing Niyad, an anticoagulant for critically ill patients undergoing kidney support treatment, which is not yet approved.

Talphera's entire value is concentrated in Niyad, a nafamostat-based anticoagulant for critically ill patients on continuous renal replacement therapy, where heparin carries bleeding risk and regional citrate is operationally complex. The thesis resolves on whether NEPHRO CRRT meets its primary endpoint before cash runs out in Q4 2026, because the contingent $12M second closing that funds a PMA submission is contractually tied to that result. A single-arm or externally controlled registrational dataset, if that is what the trial produces, raises approvability risk even with Breakthrough designation in hand.

Status
Challenged
Conviction

Current Thesis Drivers

  • 75% enrollment reached; study completion expected year-end 2026
  • BTD granted for Niyad in CRRT anticoagulation
  • Cash cliff Q4 2026 coincides with trial readout window
  • Second $12M tranche contingent on primary endpoint and stock price trigger

What could change the thesis?

  • NEPHRO CRRT primary endpoint: hit unlocks $12M tranche and PMA path; miss is terminal
  • PMA approvability: FDA accepts registrational data, or novel endpoint raises CRL risk
  • Stock VWAP trigger: met alongside endpoint, or tranche lapses despite trial success

Generated from public SEC filings and disclosures. For informational purposes only — not investment advice. Always conduct your own research before making investment decisions.

Thesis log

Tracked in real time as it happened — not reconstructed after the fact

Key value driver

The most decisive event ahead

Bull and bear case

Both sides of the thesis, argued

Pipeline

1 programs · 3 catalysts

Stress Test